Retatrutide for Weight Loss: 24.2% Average Body Weight Reduction

In June 2023, the New England Journal of Medicine published the Phase 2 clinical trial results for retatrutide that reshaped expectations for what weight loss medications can achieve. Led by Ania Jastreboff of Yale University — the same researcher who led key tirzepatide obesity trials — the study showed that retatrutide produced an average of 24.2% body weight reduction at the highest dose in just 48 weeks, with no sign of plateau. This article provides a comprehensive analysis of every weight loss data point from that landmark trial and explains what these numbers mean in real-world terms.

The Study: Design and Population

The Phase 2 trial (ClinicalTrials.gov NCT04881706) was a randomized, double-blind, placebo-controlled dose-finding study conducted at clinical sites across the United States. It enrolled 338 adults meeting the following criteria: BMI of 30 or greater (obesity), or BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. Patients with type 2 diabetes were excluded from this particular trial (a separate Phase 2 trial studied retatrutide in T2D patients).

Participants were randomized to receive weekly subcutaneous injections of retatrutide at target doses of 1 mg, 4 mg, 8 mg (with two different titration speeds), or 12 mg, or placebo. Treatment lasted 48 weeks, with a 4-week follow-up period. The primary endpoint was percent change in body weight from baseline to 24 weeks, with a key secondary endpoint at 48 weeks.

Baseline Characteristics

The Headline Results: Weight Loss by Dose

Breaking Down the 12 mg Results

The 12 mg group — the highest dose tested — deserves detailed examination because it represents the peak of retatrutide's demonstrated efficacy.

An average loss of 24.2% of body weight in 48 weeks is the most ever recorded for any weight loss drug in a clinical trial. For context, a person starting at 295 pounds would weigh approximately 224 pounds after 48 weeks — a loss of 71 pounds. Perhaps more remarkably, this average includes some participants who lost less. Looking at the distribution of results: 83% of participants lost more than 15% of their body weight, 63% lost more than 20%, and 26% lost more than 30% of their body weight.

That last number — 26% of participants losing more than 30% of their body weight — is extraordinary. A 30% weight loss from 295 pounds means dropping to 207 pounds, a loss of 88 pounds. This level of weight loss was previously achievable only through bariatric surgery. Retatrutide is the first medication to deliver surgery-equivalent results to a substantial proportion of patients.

The Weight Loss Curve: No Plateau at 48 Weeks

One of the most scientifically significant findings from the Phase 2 trial is that weight loss had not plateaued at 48 weeks in the 8 mg and 12 mg groups. The weight loss curves were still trending downward when the study ended.

This stands in contrast to semaglutide, where weight loss typically plateaus around 60-68 weeks, and tirzepatide, where the rate of loss decelerates significantly by 72 weeks. The lack of plateau with retatrutide suggests that the glucagon receptor's contribution to increased energy expenditure may prevent the metabolic adaptation that causes weight loss to stall with other drugs.

The implication is profound: if retatrutide treatment continued for 72 or 96 weeks (as Phase 3 trials with longer durations will test), total weight loss could potentially reach 28-32% or even higher. This would represent a paradigm shift in what pharmacological treatment can achieve for obesity.

BMI Changes

With a mean baseline BMI of approximately 37 kg/m2 (Class II obesity), the 12 mg group's 24.2% weight loss translates to a BMI reduction of approximately 9 points — from 37 to approximately 28 kg/m2. This moves the average participant from Class II obesity to the overweight category, just above the normal-weight cutoff of 25.

Among the 26% who lost more than 30% of body weight, many would have moved from Class II or III obesity directly into the normal BMI range (18.5-24.9). This level of BMI normalization is rarely achieved with any non-surgical intervention and has profound implications for long-term health outcomes.

Waist Circumference Reduction

Waist circumference is a critical health metric because it correlates with visceral (abdominal) fat, which is the most metabolically dangerous type of fat. Visceral fat is strongly associated with insulin resistance, cardiovascular disease, and systemic inflammation.

In the Phase 2 trial, the 12 mg group showed substantial reductions in waist circumference. From a baseline of approximately 44 inches (112 cm), participants lost an average of approximately 8-9 inches from their waist. This magnitude of waist reduction indicates significant visceral fat loss — not just subcutaneous fat — and is consistent with the glucagon receptor's known effect of preferentially mobilizing visceral fat stores.

Metabolic Improvements Beyond Weight

Weight loss of this magnitude produces widespread metabolic improvements. While the Phase 2 trial in patients without diabetes did not focus on metabolic endpoints as primary outcomes, the reported data showed significant improvements across multiple markers:

• Blood pressure: Systolic and diastolic blood pressure decreased significantly, with many participants moving from hypertensive to normotensive ranges.
• Lipids: Triglycerides decreased substantially, and the overall lipid profile improved.
• Fasting glucose and insulin: Even in participants without diabetes, fasting glucose and insulin levels improved, indicating enhanced insulin sensitivity.
• Liver fat: Retatrutide produced dramatic reductions in hepatic steatosis (liver fat content), with some data suggesting near-complete resolution of fatty liver in many participants. This is attributed to the glucagon receptor's direct effects on hepatic lipid metabolism.
• Inflammatory markers: C-reactive protein and other inflammatory markers declined, consistent with reduced visceral fat and improved metabolic health.

What These Numbers Mean in Real Life

Clinical trial percentages can feel abstract. Here is what 24.2% weight loss actually looks like for people at different starting weights:

For a 5'10" male starting at 295 pounds (BMI 42.3), losing 71 pounds brings them to 224 pounds (BMI 32.1) — moving from Class III obesity to Class I. With continued treatment beyond 48 weeks, further reductions are expected. For a 5'4" female starting at 250 pounds (BMI 42.9), losing 61 pounds brings her to 189 pounds (BMI 32.4). These are transformative, life-changing results.

How Retatrutide Compares to Bariatric Surgery

The comparison to bariatric surgery is increasingly relevant at these weight loss levels:

• Gastric sleeve (sleeve gastrectomy): Produces approximately 25-30% excess weight loss in the first year, or roughly 15-20% of total body weight. Retatrutide exceeds this at its highest dose.
• Gastric bypass (Roux-en-Y): Produces approximately 30-35% of total body weight loss over 1-2 years. Retatrutide's 24.2% at 48 weeks approaches this, and the lack of plateau suggests longer treatment could match or exceed it.
• Retatrutide advantages: Reversible (stop the injection and effects fade), no surgical risks, no anatomical alteration, easier to initiate, and accessible through telehealth platforms like Trimi.
• Surgery advantages: One-time procedure (though requiring lifelong follow-up), long track record, may be covered by insurance more readily.

What to Do While Waiting for Retatrutide

These results are exciting, but retatrutide is not yet available for prescription. If you are motivated by this data to start your weight loss journey, Trimi offers semaglutide and tirzepatide today. Tirzepatide produces approximately 22.5% average weight loss — nearly as much as retatrutide in Phase 2 — and is available now. Starting treatment immediately produces real health benefits, and patients can transition to retatrutide when it becomes available. Learn how Trimi works.

Frequently Asked Questions

How much weight can you lose with retatrutide?

In Phase 2 trials, the average weight loss at the highest dose (12 mg) was 24.2% of body weight over 48 weeks. For a person starting at 295 pounds, this equals approximately 71 pounds. Over a quarter of participants lost more than 30% of their body weight.

Is retatrutide more effective than Ozempic?

Based on clinical trial data, yes. Semaglutide (Ozempic/Wegovy) produces an average of 14.9% weight loss, while retatrutide's 12 mg dose produced 24.2% — approximately 60% more weight loss. Read our detailed retatrutide vs semaglutide comparison.

Does retatrutide weight loss plateau?

In the Phase 2 trial, weight loss at the 8 mg and 12 mg doses had not plateaued at 48 weeks. The weight loss curves were still trending downward, suggesting that longer treatment could yield even greater results. This is unlike semaglutide, which typically plateaus around 60 weeks.

Is 24.2% weight loss as good as bariatric surgery?

It approaches it. Gastric sleeve surgery typically produces 15-20% total body weight loss, while gastric bypass produces 30-35%. Retatrutide at 48 weeks (24.2%) falls between these, and the lack of plateau suggests longer treatment could match bypass results. Unlike surgery, retatrutide is non-invasive and reversible.

How fast does retatrutide work?

Weight loss begins within the first weeks of treatment. By 24 weeks, the 12 mg group had already lost 19.3% of their body weight. The rate of loss was approximately 2% per month at the maintenance dose, with no sign of slowing at 48 weeks.

Will I gain weight back if I stop retatrutide?

Based on data from other GLP-1 receptor agonists, weight regain is likely if treatment is stopped, as the appetite-suppressing and metabolic effects are drug-dependent. This is consistent across the entire drug class and underscores the importance of viewing obesity as a chronic condition requiring ongoing management.